Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
Publishing timestamp: 2024-02-29 08:16:07
Summary
Pfizer's vaccine against respiratory syncytial virus remains effective for older adults over two seasons, with slight decline in efficacy. Advisory panel to CDC to consider whether seniors should take RSV shots annually or every other year. Moderna hopes to launch its own RSV jab. GSK's shot showed cumulative efficacy of 67.2% over two seasons. Pfizer's shot recorded about $890 million in revenue in 2023.
Sentiment: NEUTRAL
Tickers: PFE, GSK-GB, GSK, MRNA,
Keywords: biotechnology, moderna inc, business, biotech and pharmaceuticals, gsk plc, breaking news, business news, pfizer inc, health care industry, pharmaceuticals,
Source: https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html